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INTRODUCTION: 
The major objective of oral controlled drug delivery  
system is todeliver drugs for longer period of time  to 
achieve betterbioavailability, which should be predictable 
and reproducible.But this is difficult due to number of 
physiological problems such as fluctuation in the gastric 
emptying process, narrowabsorption window and stability 
problem in the intestine. An Ideal drug delivery system 
should possess two main properties:  
(1) It should be a single dose for the whole 
duration of the treatment.  
(2) It should deliver the active drug directly at the 
site of action
1
.    
Gastroretentive drug delivery system (GRDDS) is one of 
the novel approach in this area.Oral controlled release 
dosage forms are the mostcommonly formulated but still 
offer highest attentionin the area of novel drug delivery 
systems
2
. Drugs that areeasily absorbed from 
gastrointestinal tract (GIT) and have short half-lives are 
eliminated quicklyfrom the systemic circu lation. Frequent 
dosingof these drugs is required to achieve 
suitabletherapeutic activity. To avoid this limitation,the 
development of oral sustained-controlledrelease 
formulat ions is an attempt to release thedrug slowly into 
the GIT and maintain an effective drug concentration inthe 
systemic circulat ion for a long time. Afteroral 
administration, such a drug delivery wouldbe retained in 
the stomach and release the drugin a controlled manner, so 
that the drug could besupplied continuously to its 
absorption sites in the GIT.
3
 
Poor absorption of many drugs in the lower GIT 
necessitates controlled release dosage forms to be 
maintained in the upper GI tract, particularly the stomach 
and upper small intestine.
4
These drugdelivery systems 
suffer from main ly twoadversities: the short gastric 
retention time(GRT) and unpredictable short gastric 
emptyingtime (GET), which can result in incomplete 
drugrelease from the dosage form in the absorptionzone 
(stomach or upper part of small intestine)leading to 
dimin ished efficacy of administered dose.
5
 To formulate a 
site-specific orallyadmin istered controlled release dosage 
form, itis desirable to achieve a prolong gastricresidence 
time by the drug delivery.  
 
Figure 1: (a) Conventional Dosage Form and (b) Gastric 
Retentive Drug Delivery System (ref. https://data.epo.org/)  
GRDDS are thus beneficial for such drugs by improving 
their bioavailability, therapeutics efficacy and possible 
reduction of the dose and improves the drug solubility that 
is less soluble in a high pH environment.
6
 Apart of these 
advantages, these systems offer various pharmacokinetics 
advantages like maintenance of constant therapeutic levels 
over a prolonged period and thus reduction in fluctuation 
in the therapeutic levels.
7
 Gastric retention will provide 
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advantages such as the delivery of drugs with narrow 
absorption windows in the s mall intestinal reg ion. Also 
prolonged gastric retention time in the stomach could be 
advantageous for localaction in the upper part of the small 
intestine. 
PHYS IOLOGY OF STOMACH: 
 
Figure 2: Physiology of stomach (ref 
http://www.zuniv.net/physiology/book/chapter22.html)  
The stomach is an organ with a capacity for storage and 
mixing. Anatomically the stomach is divided into three 
regions: Fundus, Body and antrum (pylorus). The proximal 
part made up of fundus and body which acts as a reservoir 
for undigested material, whereas the antrum is the main  
site for mixing motions and act as a pump for gastric 
emptying by propelling actions.
8
 Under fasting conditions, 
the stomach is a collapsed bag with a residual volume of 
approximately 50ml and contains a small amount of gastric 
flu id (pH 1–3) and air. The mucus spreads  and covers the 
mucosal surface of the stomach as well as the rest of the 
GI tract. The GI tract is in a state of continuous motility 
consisting of two modes,  interdigestive motility pattern 
and digestive motility pattern. The former is dominant in 
the fasted state with a primary function of clean ing up the 
residual content of the upper GIT. The interdigestive 
motility pattern is commonly called the „migrat ing motor 
complex‟ („MMC‟) and is organised in cycles of activity 
and quiescence.
9 
NEEDS  FOR GAS TRO RETENTION 
11
 
 ·Drugs that are absorbed from the proximal part of 
the gastrointestinal tract (GIT).  
 ·Drugs that are less soluble or are degraded by the 
alkaline pH they encounters at the lower part of 
GIT.  
 ·Drugs that are absorbed due to variable gastric 
emptying time.  
 ·Local or sustained drug delivery to the stomach and 
proximal Small intestine to treat certain conditions.  
 ·Part icularly useful for the treatment of peptic ulcers 
caused by H. Pylori Infections.  
IDEAL DRUG CHARACTERIS TICS FOR GRDDS 
6 
1. Drugs acting locally in the stomach, e.g. Antacids and 
drugs for H. Pylori viz., Misoprostol 
2. Drugs that are primarily absorbed in the stomach and 
upper part of GI, e.g. Amoxicillin, Calcium Supplements, 
Chlord iazepoxide and Cinnarazine  
3. Drugs that is poorly soluble at alkaline pH, e.g. 
Furosemide, Diazepam, Verapamil HCL, 
Chlord iazepoxide etc. 
4. Drugs with a narrow window of absorption in GIT, e.g. 
Riboflavin, ParaAminobenzoic Acid, Cyclosporine, 
Methotrexate, Levodopa etc. 
5. Drugs which are absorbed rapidly from the GI tract. e.g. 
Metonidazole, tetracycline. 
6. Drugs that degrade or unstable in the colon. e.g. 
Captopril, Ranit idine HCL, Metronidazol, Metformin HCl.  
7. Drugs that disturb normal colonic microbes , e.g. 
Amoxicillin Trihydrate, antibiotics against Helicobacter 
pylori. 
UNS UITABLE DRUGS FOR GRDDS 
12 
1. Drugs that have very limited acid solubility. e.g. 
phenytoin etc. 
2.Drugs that suffer instability in the gastric environment. 
e.g. erythromycin etc. 
3.Drugs intended for selective release in the colon. e.g. 5- 
amino salicylic acid and corticosteroids etc. 
FACTORS CONTROLLING GRDDS  
The stomach anatomy and physiology contain parameters 
to be considered in the development of gastroretentive 
dosage forms. To pass through the pyloric valve in to the 
small intestine the particle size should be in the range of 1 
to 2 mm.
13
 The most important parameters controlling the 
GRT of oral dosage forms include : density, size, shape of 
the dosage form, food intake and its nature, caloric 
content, frequency of intake, posture, gender, age, sex, 
sleep, body mass index, physical activ ity, diseased states 
of the individual ( e.g. chronic disease, diabetes etc.) and 
administration of drugs with impact on GI transit time.for 
example drugs acting as anticholinergic agents  ( e.g. 
atropine, propantheline), Opiates ( e.g. codeine) and 
prokinetic agents ( e.g. metclopramide, cisapride.) 
14
. The 
molecular weight and lipophilicity of the drug depending 
on its ionizat ion state are also important parameters.
15
 
A. Dosage form related factors 
Density of dosage forms: Dosage forms having a density 
lower than the gastric contents can float to the surface, 
while high density systems sink to bottom of the 
stomach.
16
 Both positions may isolate the dosage system 
from the pylorus. A density of < 1.0 gm/ cm3 is required to 
exhibit floating property.
17 
However; the floating tendency 
of the dosage form usually decreases as a function of time, 
as the dosage form gets immersed into the fluid, as a result 
of the development of hydrodynamic equilibriu m. 
18
 
Size of the dosage form: The mean GRT of nonfloating 
dosage forms are highly variable and greatly dependent on 
their size, which may be large, medium and small units.
19
 
In most cases, the larger the dosage form the greater will 
be the GRT due to the larger size of the dosage form 
would not allow this to quickly pass through the pyloric 
antrum into the intestine
20
. Dosage forms having a 
diameter of more than 7.5 mm show a better gastric 
residence time compared with one having 9.9 mm 
17
. Thus 
the size of the dosage form appearsto be an important 
factor affecting gastric retention. 
20
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Shape of the dosage form: Ring-shaped and tetrahedron-
shaped devices have a better gastric residence time as 
compared with other shapes 
21
. 
Single or multiple unit formulation: Multiple unit  
formulat ions show a more predictable releaseprofile and 
insignificant impairing of performancedue to failu re of 
units, allow co-admin istration ofunits with different release 
profiles or containingincompatible substances and permit a 
largermargin of safety against dosage form 
failurecompared with single unit dosage forms.  
B. Food intake and its nature 
Thepresence or absence of food in the GIT influences the 
GRT of the dosage form.Usually the presence offood in 
the GIT improves the GRT of the dosage form andthus, the 
drugs absorption increases by allowing itsstay at the 
absorption site for a longer period.Again, increase in  
acidity and caloric value showsdown gastric emptying time 
and improve the gastric retention of dosage forms
22
. Food 
habits affect the GRT in the fo llowing ways 
23
. 
Fed or unfed state – under fasting conditions, theGI 
motility is characterized byperiods of the 
migrat ingmyoelectric complex (MMC) that occursevery 
1.5 to 2 hours. The MMC sweeps undigestedmaterial from 
the stomach and, if thetiming of admin istration of the 
formulat ioncoincides with that of the MMC, the GRT of 
theunit can be expected to be very short. However, inthe 
fed state, MMC is delayed and GRT isconsiderably longer. 
It was concluded that as mealswere given at the time when 
the previous digestivephase had not completed, the 
floating form buoyantin the stomach could retain its 
position for anotherdigestive phase as it was carried by the 
peristalticwaves in the upper part of the stomach. 
Nature of meal – feeding of indigestible polymersor fatty 
acid salts can change themotility pattern of the stomach to 
a fed state, thusdecreasing the gastric emptying rate 
andprolonging drug release. 
Caloric content –  GRT can be increased by four to10 
hours with a meal that is high inproteins and fats. 
Frequency of feed – the GRT can increase by over400 
minutes when successive mealsare g iven compared with a 
single meal due to thelow frequency of MMC. 
C. Patient related factors 
Gender : Generally femalesshowed comparatively shorter 
mean ambulatoryGRT than males, and the gastric 
emptying inwomen was slower than in men.
24 
Age: In case of elder persons, gastric emptying is slowed 
down, especially those over 70, have a significantly longer 
GRT; 
Posture: GRT can vary between supine and upright 
ambulatory states of the patient; the floating and non-
floating systems behaved differently. In the 
uprightposition, the floating systems floated to the top 
ofthe gastric contents and remained for a longer time,  
showing prolonged GRT. But the non-floating unitssettled 
to the lower part of the stomach andunderwent faster 
emptying as a result of peristaltic contractions and the 
floating units remained awayfrom the pylorus. However, in  
supine position, thefloating units are emptied faster than 
non-floatingunits of similar size. 
Concomitant drug administration 
anticholinergics like atropine and propantheline, opiates 
like codeine and prokinetic agents like metoclopramide 
and cisapride. 
D. Disease states: 
Gastric ulcer, diabetes, hypothyroidism increase GRT. 
Hyperthyroidism, duodenal ulcers decrease GRT. 
E. Volume of GI fluid: 
The resting volume of the stomach is 25 to 50 ml. When 
volume is large, the emptying is faster. Flu ids taken at 
body temperature leave the stomach faster than colder of 
warmer flu ids. 
F. Effect of buoyancy 
On comparison of floating and nonfloating units, it 
wasconcluded that regardless of their sizes the floating 
units remained buoyant on thegastric contents throughout 
their residence in the GIT, while the non-floating units 
sank and remained in the lower part of thestomach. 
Floating units away from the gastro-duodenal junction 
were protected from theperistaltic waves during digestive 
phase while then on floating forms stayed close to the 
pylorus andwere subjected to propelling and retropelling 
waves of the digestive phase.
25 
TYPES OF DOSAGE FORM FOR GRDDS: 
A) FLOATING DRUG DELIVERY S YSTEMS  
(FDDS) AND ITS MECHANIS M: 
FDDS is one of the important approaches to achieve 
gastric retention to obtain sufficient drug bioavailability 
26
. 
This system is desirable for drugs with anabsorption 
window in the stomach or in the uppersmall intestine
27
. 
This have a less density then gastric fluids and so remain  
buoyant in thestomach without affecting gastric emptying 
rate fora pro longed period and the drug is released 
slowlyas a desired rate from the system. After release 
ofdrug, the residual system is emptied from thestomach. 
This results in an increased GRT and a better control of the 
fluctuation in plas ma drugconcentration. 
The major requirements for FDDS are 
28
: 
 It should release contents slowly to serve as a 
reservoir. 
 It must maintain specific g ravity lower than gastric 
contents (1.004 – 1.01 gm/cm3). 
 It must form a cohesive gel barrier 
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Figure 3: Mechanism of floating systems, GF= Gastric fluid (ref. http://www.pharmainfo.net/pharma-student-
magazine/comprehensive-review-floating-tablets) 
The inherent low density can be provided by 
theentrapment of air (e.g . hollow chambers)
29
 or bythe 
incorporation of low density materials (e.g. fattymaterials 
or oils, or foam powder)
30-32
. Thesefollowing approaches 
have been used for the designof floating dosage forms of 
single and multip le-unitsystems. Recently a single-unit 
floating system was proposed consisting of polypropylene 
foam powder, matrix fo rming polymers, drug and filler
33
. 
The good floating behaviour of systems could 
besuccessfully combined with accurate control of 
theresulting drug release patterns. Single-unit dosageforms 
are associated with problems such as stickingtogether or 
being obstructed in the GIT which may produce irritation. 
On theother hand multip le-unit floating systems may be 
anattractive alternative since they have been shown to 
reduce inter and intra- subject availabilit ies indrug 
absorption as well as to lower the possibility of dose 
dumping. Various mult iple-unit floatingsystem like air 
compartment mult iple-unit system, hollow microspheres 
(microballoons) preparedby the emulsion solvent diffusion 
method
 34
, micropart icles based on low density foam 
powder
31
, beads prepared by emulsion gelatin method
 
35
etc. can be distributed widely throughout the GIT,  
providing the possibility of achieving a longerlasting and 
more reliable release of drugs.Based onthe mechanism of 
buoyancyFDDS can be div ided as below: 
I. Effervescent S ystems 
These buoyant systems utilize matrices prepared with 
swellable polymers such as methocel, polysaccharides 
(e.g., ch itosan), effervescentcomponents (e.g., sodium 
bicarbonate, citric acidor tartaric acid). The system is so 
prepared thatupon arrival in the stomach, CO2 isreleased, 
causing the formulation to float in thestomach. Other 
approaches and materials that havebeen reported are a 
mixture of sodium alginate andsodium 
bicarbonate
17
,multip le unit floating pills that generate CO2 
when ingested, floating min icapsules witha core of sodium 
bicarbonate, lactose and poly vinyl pyrrolidone coated 
with hydroxyl propyl methyl cellulose (HPMC), and 
floating systemsbased on ion exchange resin technology, 
etc. 
a. Volatile liquid containing systems- 
This type of system consists of two chambers separated by 
an impermeable, pressure-responsive, movable bladder. 
The first chamber contains the drug and the second 
chamber contains the volatile liquid. TheGRT of a drug 
delivery system can be sustained by incorporating an 
inflatable chamber, which contains a liquid e.g. ether, 
cyclopentane, that gasifies at body temperature to cause 
the inflatation of the chamber in the stomach. The device 
may also consist of a bioerodible plug made up of Poly 
vinyl alcohol, Po lyethylene, etc. that gradually dissolves 
causing the inflatable chamber to release gas and collapse 
after a predetermined time to permit the spontaneous 
ejection of the inflatable systems from the stomach
36
. The 
device inflates, and the drug iscontinuously released from 
the reservoir into the gastric flu id. 
 
Figure 4: Volatile liquid containing system (ref. 
http://www.sciencedirect.com/science/article/pii/S0168365999002047) 
b. Gas – generating systems-  
These buoyant delivery systems utilize 
effervescentreaction between carbonate/bicarbonate salts 
andcitric/tartaric acid to liberate CO2, which getsentrapped 
in the gellified hydrocollo id layer of thesystems, thus 
decreasing its specific gravity andmaking it float over 
chyme
36,37
. The optimal stoicheometric ratioof cit ric acid  
and sodium bicarbonate for gasgeneration is reported to be 
0.76: 1. 
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Figure 5: a) Floating pill b) Principle mechanism of floating 
by CO2 gas releasing method 
(ref.www.pharmastuff.blogspot.com) 
A new multip le type of floating dosage system composed 
of effervescent layers and swellable membrane layers 
coated on sustained release pills. The inner layer of 
effervescent agents containing sodium b icarbonate and 
tartaric acid was divided into two sublayers to avoid direct 
contact between the two agents. These sublayers were 
surrounded by a swellable polymer membrane containing 
polyvinyl acetate and purified shellac. When this system 
was immersed in the buffer at 37ºC, it settled down and the 
solution permeated into the effervescent layer through the 
outer swellab le membrane. CO2 was generated by the 
neutralization reaction between the two effervescent 
agents, producing swollen pills (like balloons) with a 
density less than 1.0 g/ml. It was found that the system had 
good floating ability independent of pH and viscosity and 
the drug (Para‐amino benzoic acid) released in a sustained 
manner as shown in Fig.5
37
. 
II. Non-Effervescent FDDS 
Non-effervescent FDDS are normally prepared from gel-
forming or highly swellable cellulose type hydrocolloids, 
polysaccharides or matrix fo rming polymers like 
polyacrylate, polycarbonate, polystyrene and 
polymethacrylate. In one approach, intimate mixing of 
drug with a gel forming hydrocolloid which results in 
contact with gastric flu id after oral administration and 
maintain a relative integrity of shape and a bulk density 
less than unity within the gastric environment
38
. The air 
trapped by the swollen polymer confers buoyancy to these 
dosage forms. Excip ients used most commonly in these 
systems includeHPMC polyacry lates, polyvinyl acetate, 
carbopol, agar, sodium alg inate, calcium chloride, 
polyethylene oxide and polycarbonates. This system can 
be further divided into the sub-types: 
a. Hydrodynamically balanced systems OR Colloidal  
Gel Barrier System: 
Thesesystems contains drug with gel-forming 
hydrocolloids meant to remain buoyant on the stomach 
content. This prolongsGRT and maximizes the amount of 
drug that reaches its absorption sites in the solution form 
forready absorption.These are single-unit dosageform, 
containing one or more gel-forminghydrophilic 
polymers
39
. HPMC, hydroxethyl cellu lose, hydroxypropyl 
cellu lose, sodiumcarboxymethyl cellu lose, 
polycarbophil,polyacrylate, polystyrene, agar, 
carrageenans oralginic acid are used
40, 41
.  
 
Figure 6: Working principle of hydrodynamically 
balanced system (ref. www.sciencedirect.com) 
The polymer is mixedwith drugs and usually administered 
in HB-capsule. Thecapsule shell dissolves in contact with 
water andmixture swells to form a gelat inous barrier, 
whichimparts buoyancy to dosage form in gastric juice 
fora long period. Because, continuous erosion of the 
surface allows water penetration to the inner layers 
maintaining surface hydration and buoyancy to dosage 
form
41
. Incorporation of fatty excip ients  gives low-density 
formulat ions reducing theerosion. Madopar LP®, based on 
the system wasmarketed during the 1980‟s 43. Effective 
drugdeliveries depend on the balance of drug loadingand 
the effect of polymer on its release profile.Several 
strategies have been tried and investigatedto improve 
efficiencies of the floating hydro dynamically balanced 
systems 
41,42
. 
b. Microporous compartment system 
Thistechnology is based on the encapsulation of a 
drugreservoir inside a microporous compartment with  
pores along its top and bottom walls. Theperipheral walls 
of the drug reservoir compartmentare completely sealed to 
prevent any direct contactof gastric surface with the un-
dissolved drug. In thestomach, the floatation chamber 
containingentrapped air causes the delivery system to 
floatover the gastric content. Gastric flu id entersthrough 
the aperture dissolves the drug and carriesthe dissolved 
drug for continuous transport acrossthe intestine for 
absorption
43
. 
c. Alginate beads 
Multi-unit floatingdosage forms have been developed from 
freezedriedcalcium alg inate. Spherical beads 
ofapproximately 2.5 mm in dia meter can be preparedby 
dropping sodium alginate solution into aqueoussolution of 
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calcium chloride, causing theprecipitation of calcium 
alginate. The beads arethen separated, snap-frozen in  
liquid  nitrogen, andfreeze-dried at -40ºC for 24 hours, 
leading to theformat ion of a porous system, which can 
maintain afloating force for over 12 hours. These 
floatingbeads gave a prolonged residence time of morethan 
5.5 hours.
44
 
d. Microballoons or  Hollow Micros pheres 
Microballoons / hollow microspheres loaded withdrugs in 
their other polymer shelf were prepared bysimple solvent 
evaporation or solvent diffusion method to prolong the 
GRT of the dosage form. 
 
Figure 7: Formulation of floating hollow microsphere or microballoon (ref. www.pharmainfo.net)  
Commonly used polymers to develop these systems are 
polycarbonate, cellulose acetate, calciumalginate, Eudragit  
S, agar and low methoxylated pectin etc. Buoyancy and 
drug release from dosageform are dependent on quantity of 
polymers, theplasticizer polymer ratio and the solvent used 
forformulation. These microballoons floated continuously 
over the surface of an acidic  dissolution media containing 
surfactant for >12 hours. At present hollow microspheres 
are considered to be one of the most promising 
buoyantsystems because they combine the advantages 
ofmultip le-unit system and good floating
45
. 
B. BIO/MUCO–ADHES IVE S YSTEMS : 
Bioadhesive drug delivery systems (BDDS) are used as a 
delivery device within the lumen toenhance drug 
absorption in a site specific manner. This approach 
involves the use of bioadhesive polymers, which can  
adhere to the epithelial cell surface o r mucin in the 
stomach. It increases the GRT by increasing the intimacy  
and duration of contact between the dosage form and the 
biological membrane. The adherence to the gastric wall 
increases residence time at a part icular site, thereby 
improving bioavailab ility
 46
. Gastric mucoadhesion does 
not tend to be strongenough to impart to dosage forms the 
ability toresist the strong propulsion forces of the 
stomachwall. The continuous production of mucous by 
thegastric mucosa to replace the mucous that is lostthrough 
peristaltic contractions and the dilution ofthe stomach 
content also seem to limit the potentialof mucoadhesion as 
a gastroretentive force. Someof the most promising 
excip ients that have been used are polycarbophil, carbopol, 
lectins, chitosan andgliadin, etc. BDDS are used as a 
delivery device within the human to enhance 
drugabsorption in a site-specific manner
47
. 
 
Figure 8: Bio-adhesion System (ref. 
www.sciencedirect.com) 
The basis of adhesion in that a dosageform can stick to the 
mucosal surface by different mechanism. These 
mechanis ms 
[43,49
 are: 
1) The wetting theory, which is basd on the abilityof 
bioadhesive polymers to spread and developintimate 
contact with the mucous layers. 
2) The diffusion theory which proposes physical 
entanglement of mucin  strands the flexible  polymer chains, 
or an interpenetration of mucinstrands into the porous 
structure of the polymersubstrate. 
3) The absorption theory, suggests that bioadhesion due to 
secondary forces such as Vander Waalforces and hydrogen 
bonding. 
4) The electron theory, which proposes 
attractiveelectrostatic forces between the glycoprotein 
mucin network and the bio adhesive material.  
Binding of polymers to the mucin/epithelial surface can 
be divided into three categories: 
a. Hydration – mediated adhesion-Certainhydrophilic 
polymers have the tendency to imbibelarge amount of 
water and become sticky, therebyacquiring b ioadhesive 
properties. The prolonged gastroretention of the bio/muco-
adhesive delivery system is further controlled by the 
dissolution rateof the polymer.  
b. Bonding –mediated adhesion- The adhesion of 
polymers to a mucus or epithelial cell surface involves 
various bonding mechanis ms including physical, 
mechanical and chemical bonding.Physical ormechanical 
bonds can result from deposition andinclusion of the 
adhesive material in the crevices ofthe mucusa. Chemical 
bonds may be either covalent (primary) or ionic 
(secondary) in nature. Secondary chemical bonds consist 
of dispersive interactions (i.e. VanderWaals interactions) 
and stronger specific interactions such as hydrogen bonds. 
The hydrophilic functional groups responsible for fo rming 
hydrogen bonds are the hydroxyl and carboxylic groups
50
. 
c. Receptor – mediated adhesion- Certainpolymers have 
the ability to bind to specificreceptor sites on the cell 
surface. The receptormediated events serves as a potential 
approach inbio/muco- adhesion, hence enhancing the 
gastricretention of dosage forms. Certain plant lectins, like 
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tomato lectins, interact specifically with the sugar groups 
present in mucus or on the glycocalyx
51
. 
C. EXPANDABLE, UNFOLDABLE AND 
SWELLABLE S YSTEMS  
A dosage form in the stomach will withstand gastrictransit 
if it bigger than pyloric sphincter. However,the dosage 
form must be small enough to beswallowed, and must not 
cause gastric obstructioneither singly or by accumulation. 
Thus, theirconfigurations 
52,53
 are required to develop 
anexpandable system to prolong GRT: 
1) A s mall configuration for oral intake, 
2) An expanded gastroretentive form, and 
3) A final s mall form enabling evacuation followingdrug 
release from the device. 
Thus, gastro-retention is improved by thecombination of 
substantial dimension with highrigidity of dosage form to 
withstand peristalsis andmechanical contractility of the 
stomach.  
 
Figure 9: Unfoldable and s wellable systems (ref. 
www.sciencedirect.com) 
Unfoldable and swellable systems have been investigated 
andrecently tried to develop an effective GRDDS. 
Unfoldable systems are made ofbiodegradable polymers. 
They are available indifferent geometric forms like 
tetrahedron, ring orplanner membrane (4 - label disc or 4 - 
limbed crossform) of bioerodible polymer compressed 
withinacapsule which extends in the stomach
54,55
. 
Swellab le systems are also retained in the GIT due to their 
mechanicalproperties. The swelling is usually results from 
osmotic absorption of water. Expandable systems have 
somedrawbacks like problematical storage of mucheasily 
hydrolysable, biodegradable polymersrelatively short-lived 
mechanical shape memory forthe unfolding system most 
difficult to industrialize and not cost effective.  Again, 
permanent retentionof rigid, large single-unit expandable 
drug deliverydosage forms may cause brief obstruction, 
intestinaladhesion and gastropathy. 
D.  HIGH DENS ITY S YSTEMS - 
Gastric contents have a density close to water (1.004 
g/cm
3
). When high density pellets is given to the patient, it 
will sink to the bottom of the stomach and are entrapped in 
the folds of the antrum and withstand the peristaltic waves 
of the stomach wall. Sedimentation has been employed as 
a retentionmechanism for pellets that are small enough to 
beretained in the rugae or folds of the stomach body near 
the pyloric region, which is the part of theorgan with the 
lowest position in an uprightposture. Dense pellets 
(approximately 3g/cm
3
) trapped in rugae also tend to 
withstand theperistaltic movements of the stomach wall. 
Withpellets, the GI transit time can be extended from 
anaverage of 5.8–25 hours, depending more ondensity than 
on the diameter of the pellets27.Commonly used 
excip ients are barium sulphate,zinc oxide, titanium dioxide 
and iron powder, etc.These materials increase density by 
up to 1.5– 2.4g/cm3. The only major drawbacks with this 
systems is that it is technically d ifficult  to manufacture 
them with a large amount of drug (>50%) and to achieve 
the required density of 2.4-2.8 g/cm
3
 
E. MAGNETIC S YS TEMS  
This approach toenhance the GRT is basedon the simple 
principle that the dosage formcontains a small internal 
magnet, and a magnetplaced on the abdomen over the 
position of thestomach. Although magnetic system seems 
towork, the external magnet must be positioned with 
adegree of precision that might compromisepatient 
compliance.The technological approach in rabbits with 
bioadhesive granules containing ultra-fine ferrite. They 
guided them to oesophagus with an external magnet for the 
initial 2 minutes and almost all the granules were retained 
in the region after 2hours
56
. 
F. RAFT FORMING S YSTEM 
Raft System incorporate alg inate gels these have a 
carbonate component and, upon reaction with gastric acid, 
bubbles form in the gel, enabling floating
57
. Raft forming 
systems have received much attention for the drug delivery 
for GI infections and disorders. Themechanism includes 
the formation ofviscous cohesive gel in contact with 
gastric fluids, wherein eachportion of the liquid swells 
forming a continuous layer called a raft.Th is raft floats on 
gastric fluids because of low bulk density createdby the 
formation of CO2. Usually, the system ingredients includes 
agel forming agent and alkaline bicarbonates or 
carbonatesresponsible for the format ion of CO2 to make 
the system less denseand float on the gastric flu ids  
 
Figure 3: Schematic illustration of the barrier formed by a 
raft-forming system. (ref. 
http://www.pharmainfo.net/reviews/gastroretentive -drug-delivery-
system-overview) 
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An antacid raft forming floating system contains a gel 
forming agent (e.g. sodium alginate), sodiumbicarbonate 
and acid neutralizer, which forms a foaming 
sodiumalginate gel (raft), which when comes in contact 
with gastric flu ids,the raft floats on the gastric flu ids and 
prevents the reflux of thegastric contents (i.e. gastric acid) 
into the esophagus by acting as abarrier between the 
stomach and esophagus
58
. 
G. SUPER POROUS HYDROGEL S YS TEMS   
These swellab le systems differ sufficiently from 
theconventional types to warrant separateclassification. 
Super porous hydrogel that expand dramat ically (hundreds 
of times their dehydrated form within a matter of seconds) 
when immersed in water. With pore size ranging, 10nm to 
10µm, absorption window by conventional hydrogel is a  
very slow process and several hours may be needed to 
reach an equilibrium state during which parameter 
evacuation of the dosage form may occur
59
. In this 
approach to improve GRT super porous hydrogel of 
average pore size less than 100µm, swell toequilibrium 
size within a minute due to rapid wateruptake by capillary  
wetting through numerousinterconnected open pores
60
. 
They swell to a largesize (swelling ratio : 100 or more) and 
are intendedto have sufficient mechanical strength to 
withstandpressure by gastric contraction. This is advised 
byco-formulation of hydrophilic particu late material
61
. 
H. SWELLING S YSTEMS   
These are the dosage forms, which after swallowing; swell 
at an extent that prevents their exit from the pylorus. As a 
result, the dosage form is retained in the stomach for a 
long period of time. These systems may be named as “plug 
type systems”, since they exhib it the tendency to remain  
lodged at the pyloric sphincter. The formulation is 
designed for gastric retention and controlled delivery of 
the drug into the gastric cavity. Such polymeric matrices 
remain in the gastric cavity for several hours even in the 
fed state. Sustained and controlled drug release may be 
achieved by selection of proper molecular weight polymer, 
and swelling of the polymer retards the drug release. On 
coming in contact with gastric fluid, the polymer imbibes 
water and swells. The extensive of these polymers is due to 
the presence of physical/chemical cross -links in the 
hydrophilic polymer network.  
 
Figure 41: Swellable tablet in stomach(ref.www.pharmainfo.net) 
ADVANTAGES  OF GAS TRORETENTIVE DRUG 
DELIVERY S YS TEMS  
1) The bioavailability of therapeutic agents can be 
significantly enhanced especially for those which get 
metabolized in the upper GIT by thisGRDDS in  
comparison to the admin istration of non-
GRDDS
62
.There are several different factors related to 
absorption and transit of the drug in the GIT that act 
concomitantly to influence the magnitude of drug 
absorption 
63
. 
2) In a similar fashion to the increased efficacy of active 
transporters exhibit ing capacity limited activity, the 
pre-systemic metabolis m of the tested compound may 
be considerably increased when the drug is presented 
to the metabolic enzymes (cytochrome P450, in  
particular CYP3A4) in a sustained manner, rather than 
by a bolus input. 
3) For drugs with relatively short half life, sustained 
release may result in a flip-flop pharmacokinetics and 
also enable reduced frequency of dosing with 
improved patientcompliance.  
4) They also have an advantage over their conventional 
system as it can be used to overcome the adversities of 
the GRT as well as the GET. As these systems are 
expected to remain buoyant on the gastric fluid  
without affecting the intrinsic rate of employing 
because of low density. 
5) GRDDS can produce prolong and sustain release of 
drugs from dosage forms which avail local therapy in  
the stomach and small intestine. Hence they are useful 
in the treatment of disorders related to stomach and 
small intestine. 
6) The controlled, slow delivery of drug form GRDF 
provides sufficient local action at the diseased site, 
thus minimizing or eliminating systemic exposure of 
drugs. This site-specific drug delivery reduces 
undesirable effects of side effects. 
7) Continuous input of the drug following CR-GRDF 
administration produces blood drug concentrations 
within a narrower range compared to the IR dosage 
forms. Thus, GRDF min imize the fluctuation of drug 
concentrations and effects.Therefore, concentration 
dependent adverse effects that are associated with 
peak concentrations can be presented. This feature is 
of special importance for drug with a narrow 
therapeutic index 
64
. 
8) Retention of the drug in the GRDF at the stomach 
minimizes the amount of drug that reaches the colon. 
Thus, undesirable activities of the drug in colon may 
be prevented. 
9) In many cases, the pharmacological response which 
intervenes with the natural physiologic processes 
provokes a rebound activity of the body that 
minimizes drug activity. Thus Slow input of the drug 
into the body was shown that gastroretentive drug 
delivery system can minimize the counter activity of 
the body leading to higher drug efficiency.  
10) Reduction of fluctuation in drug concentration makes 
it possible to obtain improved selectivity in receptor 
activation. 
11) The sustained mode of drug release from 
gastroretentive dosage form enables extension of the 
time over a critical concentration and thus enhances 
the pharmacological effects and improves the 
chemical outcomes. 
LIMITATIONS OF GASTRORETENTIVE DRUG 
DELIVERY S YS TEMS  
GRDDS have potential in improving BA of 
drugsexhibiting „absorption window‟. However theyhave 
certain limitations. One of the majordisadvantages of the 
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floating system is therequirement of h igh levels of fluids in  
the stomachfor the delivery system to float and work 
efficiently.
65 
1) Require a higher level o f fluids in the stomach.  
2) Not suitable for drugs that may cause gastric lesions 
e.g. Non- steroidal anti inflammatory drugs. Drugs 
that are unstable in the strong acidic environment, 
these systems do not offer significant advantages over 
the conventional dosage forms fo r drugs that 
are absorbed throughout the GIT. 
3) Drugs intended for selective release in the colon E.g. 
5- amino salicylic acid and cort icosteroids etc. 
4) The floating systems in patients with achlorhydria can 
be questionable in case of swellab le system. 
5) Retention of high density systems in the antrum part 
under the migrating waves of the stomach is 
questionable. 
6) The mucus on the walls of the stomach is in a state of 
constant renewal, resulting in unpredictable 
adherence. 
7) Bioadhesion in the acidic environment and high 
turnover of mucus may raise questions about the 
effectiveness of this technique. Similarly retention of 
high density systems in the antrum part under the 
migrat ing waves of the stomach is questionable. 
8) In all the above systems the physical integrity of the 
system is very important and primary requirement.  
9) The residence time in the stomach depends upon the 
digestive state. Hence FDDS should be administered 
after the meal. 
[4
 
10) The ability to float relies on the hydration state of the 
dosage form, In order to keep these tablets floating in 
vivo, intermittent admin istration of water (a tumbler 
full, every 2 hours) is beneficial.
4     
11) The ability of the drug to remain in the stomach 
depends upon the subject being positioned upright.
66 
12) Nifedipin like drug can‟t be candidate for FDDS since 
the slow gastric emptying may lead to the reduced 
systemic bio -availab ility.
67 
Table 1: Some marketed preparations of GRDDS 
available in the Market
69
 
Drug Brand name 
Diazepam Floating capsule Valrelease® 
Benserazide and L-Dopa Madopar® 
Aluminium – Magnesium antacid Topalkan® 
Antacid preparation AlmagateFlot-Coat® 
Ciprofloxacin Cifran OD 
Metformin HCL Glumetza GRTM 
Misoprostal Cyotec 
Aluminium Hydroxide Liquid Gavison 
Ferrous sulphate Conviron 
CONCLUS IONS: 
Controlled release gastroretentive dosage forms (CR-
GRDF) enable prolonged and continuous input of the drug 
to the upper parts of the gastrointestinal (GI) tract and 
improve the bioavailability of medicat ions that are 
characterized by a narrow absorption window. Based on 
the literature surveyed, it may be concluded that 
gastroretentive drug delivery offers various potential 
advantages for drug with poor bioavailability due their 
absorption is restricted to the upper gastrointestinal tract 
(GIT) and they can be delivered efficiently thereby 
maximizing their absorption and enhancing absolute 
bioavailability. And hence, it can be concluded that these 
dosage forms serve the best in the treatment of diseases 
related to the GIT and for extracting a prolonged action 
from a drug with a short half-life. 
FUTURE POTENTIAL FOR GRDDS: 
While the control of drug release profiles has been a major 
aim of pharmaceutical research and development in the 
past two decades, the control of GI transit profiles could be 
the focus of the next two decades and might result in the 
availability of new products with new therapeutic 
possibilit ies and substantial benefits for patients. Soon, the 
so-called „once-a-day‟ formulat ions may be rep laced by 
novel gastroretentive products with release and absorption 
phases of approximately 24 hours. 
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